Euro · CUSIP N71542109 · who reports it, how much, and how much it matters to them
18 of the 720 hedge fund managers we track reported shares of ProQR Therapeutics N.V. (Nasdaq: PRQR) on Form 13F for 30 June 2026. Between them they reported USD 41m. The largest position belongs to Adage Capital Management, at USD 17m. The manager with the most riding on it is M28 Capital Management, where it is 2.4% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Adage Capital Management1 fund on PPLI.com | USD 17m | 0.0% |
| 2 | Sphera Funds Management1 fund on PPLI.com | USD 3.3m | 0.4% |
| 3 | Kynam Capital Management1 fund on PPLI.com | USD 2.9m | 0.2% |
| 4 | Dafna Capital Management6 funds on PPLI.com | USD 2.8m | 0.5% |
| 5 | 683 Capital Management2 funds on PPLI.com | USD 2.6m | 0.1% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 2.2m | 0.0% |
| 7 | Platinum Investment Management11 funds on PPLI.com | USD 2.2m | 0.5% |
| 8 | Two Sigma Investments35 funds on PPLI.com | USD 2.1m | 0.0% |
| 9 | Eversept Partners3 funds on PPLI.com | USD 1.9m | 0.1% |
| 10 | Boothbay Fund Management2 funds on PPLI.com | USD 1.8m | 0.0% |
| 11 | M28 Capital Management1 fund on PPLI.com | USD 1.1m | 2.4% |
| 12 | Persistent Asset Partners10 funds on PPLI.com | USD 440,000 | 0.1% |
| 13 | Palo Alto Investors6 funds on PPLI.com | USD 351,000 | 0.0% |
| 14 | Burkehill Global Management5 funds on PPLI.com | USD 328,000 | 0.0% |
| 15 | Millennium Management6 funds on PPLI.com | USD 299,000 | 0.0% |
| 16 | POINT72 Asset Management17 funds on PPLI.com | USD 94,213 | 0.0% |
| 17 | Verdad Advisers6 funds on PPLI.com | USD 35,526 | 0.0% |
| 18 | Atom Investors1 fund on PPLI.com | USD 24,379 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | M28 Capital Management | USD 1.1m | 2.4% |
| 2 | Dafna Capital Management | USD 2.8m | 0.5% |
| 3 | Platinum Investment Management | USD 2.2m | 0.5% |
| 4 | Sphera Funds Management | USD 3.3m | 0.4% |
| 5 | Kynam Capital Management | USD 2.9m | 0.2% |
| 6 | Persistent Asset Partners | USD 440,000 | 0.1% |
| 7 | 683 Capital Management | USD 2.6m | 0.1% |
| 8 | Eversept Partners | USD 1.9m | 0.1% |
| 9 | Palo Alto Investors | USD 351,000 | 0.0% |
| 10 | Verdad Advisers | USD 35,526 | 0.0% |
ProQR Therapeutics N.V. trades under the symbol PRQR on the Nasdaq. Its CUSIP, the code used on Form 13F, is N71542109.
18 of the 720 hedge fund managers PPLI.com tracks reported ProQR Therapeutics N.V. shares on Form 13F for 30 June 2026. The largest reported positions were held by Adage Capital Management (USD 17m), Sphera Funds Management (USD 3.3m), Kynam Capital Management (USD 2.9m), Dafna Capital Management (USD 2.8m) and 683 Capital Management (USD 2.6m).
18 managers in our coverage reported it, and between them they run 146 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
M28 Capital Management, where the position was 2.4% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with ProQR Therapeutics N.V. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.